Aortic stenosis
Conditions
Interventions
Test group:PCSK9 inhibitor (subcutaneous injection, once every 2 weeks) plus statin (maximum tolerated dose) therapy
Control group:statin (maximum tolerated dose) therapy
Sponsors
Southern Medical University Southern Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily sign informed consent; 2. Age > 18 years old, gender is not limited; 3. Patients with aortic stenosis diagnosed by echocardiography; 4. Combined with atherosclerotic cardiovascular disease or hypercholesterolemia LDL-C >=4.9mmol/L; 5. Blood lipids are not up to standard after maximum tolerated dose of statins;
Exclusion criteria
Exclusion criteria: 1. Rheumatic aortic stenosis; 2. Previous use of PCSK9 inhibitors or allergy to PCSK9 inhibitors; 3. Left ventricular ejection fraction <=35%; 4. Patients who plan to undergo aortic valve replacement or TAVR in the near future; 5. Complicated with other severe valvular diseases; 6. Treatment adherence was poor and medication was not administered according to the trial protocol; 7. Pregnant and lactating women; 8. Combined with active malignant tumor, severe liver and kidney dysfunction and other life expectancy of less than 1 year; 9. Participants who are participating in other interventional clinical studies; 10. Patients who were judged by the investigator to be ineligible for participation in the trial;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak aortic valve velocity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Major adverse cardiac events;Aortic valve area;Adverse aortic events, AAE;Major adverse cardiac events, MACE; | — |
Countries
China
Contacts
Public ContactZeng Qingchun
Southern Medical University Southern Hospital
Outcome results
None listed